Delphine Aubert
25 works · 3,201 citations · h-index 10
Top works
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation
- GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patients
- Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
- Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
- Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial
- Cisplatin-Based Three Drugs Combination (NIP) as Induction and Adjuvant Treatment in Locally Advanced Non-small Cell Lung Cancer: Final Results
- Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts)
- A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)
- Oral Vinorelbine and Cisplatin with Concomitant Radiotherapy in Stage III Non-Small Cell Lung Cancer (NSCLC): A Feasibility Study
- 801 Oral chemotherapy and upper gastro-intestinal tolerance (UGT) improvement of nausea and vomiting in non-small-cell-lung-cancer (NSCLC) patients (pts) treated with oral navelbine (NVB) and standard antiemetic prophylaxis
- Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts)
- Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function
- Optimal tolerance of an all-oral combination chemotherapy (CT) of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): Safety Results of two international multicenter studies
- O-144 Result of a phase II study conducted in elderly patients with unresectable localised or metastatic non-small-cell-lung cancer (NSCLC) with oral vinorelbine given as a weekly monotherapy
- GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patientsAnn Oncol 2002; 13: 1853–1861
- Efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC): First results of an international phase II trial
- Oral vinorelbine (NVBo) + CDDP and radiotherapy (RT) in stage III non small cell lung cancer (NSCLC) patients (pts)
- Single agent oral vinorelbine (NVB) in advanced non-small cell lung cancer (NSCLC) in the elderly: Patient benefit improvement by weekly schedule
- P-544 Final results of a phase I study with navelbine (NVB) oral in combination with cisplatin (C), evaluating two different schedules in advanced non-small cell lung cancer (NSCLC) patients